drugset / Trial / NCT04507932

Characterizing Inflammatory Bowel Disease With 68Ga-FAPI PET/CT

NCT04507932

Phase 0 Unknown 100 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelDiagnostic

Summary

68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel disease. And it might be more sensitive than FDG in detecting a certain type of inflammations according to our preliminary research. Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of inflammatory bowel disease than 18F-FDG PET/CT.

Timeline

Start
2020-08-01
Primary completion
2022-01-01
Completion
2022-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject FAPI GA-68 Diagnostic / imaging agent Intravenous